Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QLG2065 vs Ozempic in Type 2 Diabetes
NCT05950516Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05950516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950516.